You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Muscarinic M1 Receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Muscarinic Receptor Occupancy Trial in New Haven (Scopolamine, [11C]EMO ([11C]LSN3172176))

Not yet recruiting
  • Muscarinic Receptor Occupancy
  • New Haven, Connecticut
    Yale University
Aug 31, 2023

Schizophrenia, Schizoaffective Disorder, Healthy Trial in New Haven (11C-EMO - A Novel PET Radiotracer for Muscarinic M1

Recruiting
  • Schizophrenia
  • +2 more
  • 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor
  • New Haven, Connecticut
    Connecticut Mental Health Center
Sep 16, 2022

Multiple Sclerosis Trial in London (PIPE-307)

Completed
  • Multiple Sclerosis
  • London, United Kingdom
    Hammersmith Medicines Research
Oct 4, 2022

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)

Not yet recruiting
  • Lymphomas
  • B-cell Lymphomas
  • Houston, Texas
    The University of Texas M D Anderson Cancer Center
Mar 6, 2023

Lung Cancer Trial in Houston (Cemiplimab, Kevzara (Sarilumab))

Not yet recruiting
  • Lung Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2023

Type 1 Diabetes Trial in La Jolla (Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo)

Completed
  • Type 1 Diabetes
  • Dapagliflozin 10 MG [Farxiga]
  • +2 more
  • La Jolla, California
    UC San Diego Altman Clinical & Translational Research Institute
Jan 20, 2023

Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

Not yet recruiting
  • Kidney Transplant Recipients
  • Dapagliflozin 10 MG
  • Semaglutide, 1.0 mg/mL
  • Toronto, Ontario, Canada
    Toronto General Hospital
Jul 6, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma Trial in

Withdrawn
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +4 more
  • Bintrafusp Alfa
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 2, 2022

Postpartum Hemorrhage Trial in Toronto (Oxytocin)

Recruiting
  • Postpartum Hemorrhage
  • Toronto, Ontario, Canada
    Mount Sinai Hospital
Oct 24, 2022

Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Houston

Completed
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Bintrafusp Alfa
  • Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
Mar 3, 2022

Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,

Recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +8 more
  • San Francisco, California
    University of California, San Francisco
May 2, 2022

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Active, not recruiting
Has Results
  • Anatomic Stage II Breast Cancer AJCC v8
  • +16 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Schizophrenia Trial in Boston (CVL-231)

Recruiting
  • Schizophrenia
  • Boston, Massachusetts
    Massachusetts General Hospital Translational and Clinical Resear
Jul 6, 2022

Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma Trial in

Active, not recruiting
  • Anatomic Stage IIIB Breast Cancer AJCC v8
  • +4 more
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Sep 30, 2022

Carcinoma, Ductal, Breast, Breast Cancer, Breast Tumor Trial in Worldwide (G1T38, Fulvestrant)

Active, not recruiting
  • Carcinoma, Ductal, Breast
  • +2 more
  • Sofia, Bulgaria
  • +7 more
Aug 1, 2022

Intracerebral Haemorrhage Trial in Manchester (IL-1Ra Kineret®, IL-1Ra Placebo)

Completed
  • Intracerebral Haemorrhage
  • IL-1Ra Kineret®
  • IL-1Ra Placebo
  • Manchester, North West, United Kingdom
    Salford Royal NHS Foundation Trust
Oct 4, 2021

Type 1 Diabetes With Diabetic Nephropathy Trial in Worldwide (Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin)

Not yet recruiting
  • Type 1 Diabetes Mellitus With Diabetic Nephropathy
  • Aurora, Colorado
  • +6 more
Oct 2, 2023

Metastatic Solid Tumors, Esophageal Cancer, NSCLC Trial in Houston, San Antonio, Toronto (M1231)

Recruiting
  • Metastatic Solid Tumors
  • +2 more
  • Houston, Texas
  • +2 more
Jul 29, 2022

Glioblastoma Trial in Worldwide (RO7428731)

Recruiting
  • Glioblastoma
  • Melbourne, Victoria, Australia
  • +4 more
Aug 2, 2022

Edema, Erythema, Estrogen Receptor Negative Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)

Active, not recruiting
  • Edema
  • +8 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Jan 23, 2023

Chronic Kidney Diseases Trial in Worldwide (Zibotentan, Dapagliflozin, Placebo)

Enrolling by invitation
  • Chronic Kidney Diseases
  • Aurora, Colorado
  • +5 more
Oct 18, 2022

BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston, Seattle (Educational Intervention, Genetic

Recruiting
  • BARD1 Gene Mutation
  • +14 more
  • Educational Intervention
  • +3 more
  • Houston, Texas
  • +1 more
Jun 14, 2022

Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL) Trial in Canada, United States (CC-97540)

Active, not recruiting
  • Lymphoma Non-Hodgkin
  • +2 more
  • CC-97540
  • Birmingham, Alabama
  • +13 more
Oct 28, 2022